Eloralintide
LY3841136
PHASE 1/2 · AMYLIN RECEPTOR AGONIST (INVESTIGATIONAL)
▓ 34 indexed citations across PubMed (8), ClinicalTrials.gov (22), EuropePMC (4).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Mechanism of action
Long-acting amylin receptor agonist
Researched effects
Weight loss; appetite control (Phase 1/2)
Reported efficacy (trial readout)
-
Weight Loss 20%
Lancet (Phase 2, 48wk, n=263)
High confidencen=263Phase 22025
Trial-efficacy data current as of November 16, 2026.
Live evidence
Active clinical trials 17
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
- A Study Assessing Eloralintide (LY3841136) in Healthy Participants
Recent literature
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
Trial doses undisclosed
Known concerns
Early-stage trials
Top-ranked picks
10 pre-curated authoritative sources, ranked by journal tier and study weight.
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Full citation library
Year distribution
No references match — clear filters.
Meta-Analyses
1-
1.
Long-acting amylin-based therapies (ABTs) are emerging anti-obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and rank agents and doses within a network meta-analysis (NMA) framework. We conducted a frequentist random-effects NMA of randomized controlled trials comparing novel ABTs with placebo or active comparators in R. Primary outcome was the percent change in body…
Randomised Controlled Trials
3-
2.
Eloralintide (LY3841136), a novel amylin analog, was evaluated in translational studies to characterize its therapeutic potential for treating obesity. In vitro assays were performed in cell lines selectively expressing rat or human amylin 1 receptor (AMY1R), amylin 3 receptor (AMY3R), or calcitonin receptor (CTR). In vivo studies were conducted in rats and monkeys. A phase 1, randomized, placebo-controlled, participant/investigator-blinded trial evaluated the safety and tolerability of single-a…
-
3.
Amylin-based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management. We performed a phase 2, double blind, randomised, placebo-controlled trial with the aim of evaluating the efficacy and safety of a range of doses and dose escalation schemes of once-per-week eloralintide versus placebo in adults with obesity or overweight and had at least one weight-related comorbidity. We enrolled 263 participants…
-
4.
Eloralintide (LY3841136) is a potent, long-acting selective amylin receptor agonist currently under development for the treatment of obesity with once-weekly subcutaneous dosing. This 12-week Phase 1, randomised, placebo-controlled, participant- and investigator-blinded, multiple ascending dose study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamic profiles of eloralintide upon once-weekly subcutaneous dosing without dose escalation in participants with obesity or overwe…
Trial Registrations (ClinicalTrials.gov)
22-
5.
Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
-
6.
Conditions: Overweight, Obesity
-
7.
Conditions: Overweight, Obesity
- 8.
-
9.
Conditions: Kidney Disease, Renal Insufficiency Chronic, Kidney Failure, Chronic (+3)
-
10.
Conditions: Osteoarthritis, Overweight or Obesity
- 11.
-
12.
Conditions: Sleep Apnea, Obstructive, Obesity, Overweight
-
13.
Conditions: Obesity, Overweight
-
14.
Conditions: Hepatic Insufficiency
-
15.
Conditions: Obesity, Overweight
-
16.
Conditions: Overweight, Obesity
-
17.
Conditions: Obesity, Overweight
-
18.
Conditions: Obesity, Overweight
-
19.
Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2
-
20.
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
Conditions: Obesity, Overweight
-
21.
Conditions: Healthy
-
22.
Conditions: Obesity
-
23.
Conditions: Obesity, Overweight
-
24.
Conditions: Healthy Volunteers
-
25.
Conditions: Overweight, Obesity
-
26.
Conditions: Obesity, Overweight, Cardiovascular Diseases (+1)
Reviews
3-
27.
The first therapeutically useful amylin receptor (AMYR) agonist, pramlintide was based upon the structure of non-aggregating rat amylin and found limited application as an adjunct to insulin therapy. It acts centrally to induce satiety, promote weight loss, suppress prandial glucagon release and reduce prandial hyperglycaemia. Recent understanding of the heterodimeric structure of amylin-calcitonin receptor complexes and of amylin structure-function properties has assisted the design of a second…
-
28.
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss previously considered attainable only with bariatric surgery. However, GLP-1-based therapies have revealed important limitations, including weight loss plateaus, substantial inter-individual variability, and weight regain upon discontinuation, underscori…
-
29.
Type 2 diabetes mellitus (T2DM) and obesity represent two major global health challenges. Amylin-based agonists offer a promising perspective. Three frontrunner agents of this class are increasingly being investigated: zenagamtide, eloralintide and cagrilintide-semaglutide (CagriSema). A search in PubMed/MEDLINE, Scopus and Google Scholar was conducted with the use of appropriate keywords until June 2026 for this narrative review. Zenagamtide (formerly known as amycretin), a unimolecular long-la…
Research Articles
5-
30.
Obesity is a disease that is both costly and prevalent, and although the development and use of glucagon-like peptide-1 receptor agonists has dramatically altered the landscape of obesity treatment, there remains a need to identify alternate approaches to reduce body weight. Amylin, a pancreatic hormone, has been viewed as a favorable candidate for novel obesity pharmacotherapies due to its ability to suppress feeding and body weight through its actions in the brain. Although research initially…
-
31.
The islet amyloid polypeptide (IAPP) is a peptide hormone playing key biological roles, including glucose homeostasis and regulation of food intake, conferring high therapeutic potential to treat metabolic disorders. Nonetheless, IAPP is mainly known as the major component of the amyloid fibrils observed in the pancreatic islets of patients afflicted with type 2 diabetes, and the accumulation of these insoluble protein deposits correlates closely with the loss of pancreatic β-cells. The inherent…
-
32.
The development of drugs targeting Nutrient Stimulated Hormone receptors has ushered in a dramatic change in our approach to weight management because of their ability to achieve weight losses of 10%, 20%, even 30% in significant numbers of patients. Additionally, disease modifying properties of these medications are compelling. Indications now include cardiovascular risk reduction, obstructive sleep apnea and diabetes management, and emerging evidence supports efficacy for heart failure and chr…
-
33.
Obesity is a heterogeneous, complex, and chronic disease that has a detrimental impact on disability-adjusted life years across the globe. Recent advancements in our understanding of gut-brain communication at the molecular level have driven the development of next-generation anti-obesity medications (AOMs). Glucagon-like peptide-1 receptor agonists (GLP1RAs) remain the front-runners in this rapidly evolving landscape of hormone-based AOMs. Two GLP1RAs, namely Liraglutide and Semaglutide, have b…
-
34.
Obesity remains a major modifiable driver of cardiovascular disease. Emerging antiobesity pharmacotherapies demonstrate substantial weight loss alongside improvements in multiple cardiometabolic parameters. This literature review summarizes the early clinical studies of eloralintide, a selective long-acting amylin receptor agonist, and evaluates whether its weight loss and cardiometabolic effects may be relevant to cardiovascular risk reduction. Early clinical studies suggest a potentially disti…
Curated sources on file
24- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
- 7.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
- 16.
- 17.
- 18.
- 19.
- 20.
- 21.
- 22.
- 23.
- 24.